MaxCyte has entered a technology license partnership with Genentech, granting Genentech access to MaxCyte's ExPERT GTx® platform and other technologies to support cell therapy development across research, clinical development, and manufacturing. This multi-program license aims to streamline Genentech's ex vivo cell engineering efforts from early discovery through cGMP manufacturing. The deal highlights MaxCyte's role in advancing next-generation cell therapies by integrating cell engineering and gene editing technologies to accelerate therapeutic development.
Charles Schwab announced record second-quarter results with $7.07 billion in revenue and $1.62 adjusted EPS, a 42% increase year-over-year. The company added 1.4 million new brokerage accounts and $120 billion in net new assets, signaling strong clie...
D.R. Horton reported strong quarterly earnings with an EPS of $3.20 and revenue of $9.23 billion, both exceeding analyst expectations. The results were driven by a 4% increase in home-closing volumes, totaling nearly 24,000 homes, along with contribu...
The U.S. Small Business Administration (SBA) announced a $6 million grant competition to fund the Women’s Business Center (WBC) Modernization Initiative. This initiative aims to expand statewide support networks for women entrepreneurs in eight state...
Copart's stock is under pressure following a Barclays analyst downgrade to a $26 price target and significant insider selling by a company director. The company faces a securities fraud investigation after CEO Jeff Liaw's resignation, which caused an...
Charles Schwab reported strong Q2 2026 results with earnings per share of $1.62, exceeding estimates and marking a 42% increase year-over-year. The company achieved record quarterly revenue of $7.07 billion, driven by increased trading activity and h...
